Premier Alternatives

Artax Biopharma

Cambridge, MA · Founded 2013 · Privately Held (backing)

Developer of small-molecule drugs intended to treat autoimmune and inflammatory diseases. Artax Biopharma is based in Cambridge, MA and was founded in 2013. Its last reported valuation was $58 million in May 2022. It has raised $51.5 million across 8 recorded rounds; the latest was a $19 million early-stage round in Jul 2024.

Last reported valuation
$58.0M
Oct 2026
Priced at
—
Total raised
$51.5M
Last round
Early Stage VC
Jul 2024

Artax Biopharma key facts

as of Oct 2026
  • Developer of small-molecule drugs intended to treat autoimmune and inflammatory diseases.
  • Artax Biopharma is valued at approximately $58.0M as of Oct 2026 (last reported valuation).
  • It has raised $51.5M across 8 recorded rounds; the latest was Early Stage VC ($19.0M) in Jul 2024.
  • Notable investors include ABI LAB, Advent Life Sciences, Belinda Termeer, Columbus Venture Partners, Dosbio50 — 9 tracked in total.
  • Artax Biopharma has filed 10 Form Ds with the SEC since 2013, most recently Jul 2025 ($11.0M sold to 30 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$58.0M

Artax Biopharma's last reported valuation, May 2022. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Artax Biopharma with a free account
  • ·Watch Artax Biopharma: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Artax Biopharma funding rounds

8 rounds
Jul 2024Early Stage VC$19.0MSEC filing▮
Dec 2021Early Stage VC$25.8MSEC filing▮
Feb 2021Seed Round$2.2MSEC filing▮
Apr 2020Seed Round$2.0MSEC filing▮
Jul 2019Seed Round$750KSEC filing▮
Full funding history →

Artax Biopharma valuation

Artax Biopharma's last reported valuation was $58 million in May 2022. No priced round, secondary trade or fund mark has surfaced since.

How much has Artax Biopharma raised?

Artax Biopharma has raised $51.5 million across 8 recorded rounds since 2013. The largest was a $750,000 seed round in Jul 2019; the most recent was a $19 million early-stage round in Jul 2024.

Artax Biopharma has filed 10 Form Ds with the SEC since 2013, most recently in Jul 2025 ($11 million sold to 30 investors).

Artax Biopharma investors

9 investors are on record for Artax Biopharma, including ABI LAB, Advent Life Sciences, Belinda Termeer and Columbus Venture Partners. The early-stage round in Jul 2024 drew 30 investors.

About Artax Biopharma

Developer of small-molecule drugs intended to treat autoimmune and inflammatory diseases. The company's drugs eliminate harmful foreign pathogens while being tolerant of self-tissues and organs that simultaneously allow the body to fight foreign pathogens, enabling doctors to treat both the symptoms and the underlying disease with few side effects.

Sector
Healthcare
HQ
Cambridge, MA, United States
Founded
2013
Employees
11
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.